Ranceph

C₁₆H₁₇N₃O₄S347.40 g/mol

(6R,7R)-7-[[(2R)-2-Amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 27447.

Registration

Applicants: 1
Registrations: 4

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Ranbaxy (SA) (Pty) Ltd	Ranceph	125 mg/ 5ML, 250, 250 mg/5 ML, 500	300334, 300335, 320214, 320215	Not determined	None

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Ranceph 250 capsules EACH CAPSULE CONTAINS CEPHALEXIN MONOHYDRATE EQUIVALENT TO 250,0 mg CEPHALEXIN	250Capsules	30033430/20.1.1/0334	Registered	Not determined	None
Ranceph 500 capsules EACH CAPSULE CONTAINS CEPHALEXIN MONOHYDRATE EQUIVALENT TO CEPHALEXIN 500,0 mg	500Capsules	30033530/20.1.1/0335	Registered	Not determined	None
Ranceph suspension 125 mg/ 5ml EACH 5,0 ml SUSPENSION CONTAINS CEPHALEXIN MONOHYDRATE EQUIVALENT TO CEPHALEXIN 125,0 mg	125 mg/ 5MLSuspension	32021432/20.1.1/0214	Registered	Not determined	None
Ranceph suspension 250 mg/5 ML EACH 5,0 ml SUSPENSION CONTAINS CEPHALEXIN MONOHYDRATE EQUIVALENT TO CEPHALEXIN 250,0 mg	250 mg/5 MLSuspension	32021532/20.1.1/0215	Registered	Not determined	None

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Background

Loading Wikipedia summary

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Research articles

Loading PubMed articles